BridgeBio Oncology Therapeutics Inc.
Status: Publicly traded
Last reviewed: October 2026
Direct answer
BridgeBio Oncology Therapeutics Inc. is publicly traded on NASDAQ under the ticker BBOT.
BridgeBio Oncology Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of small-molecule therapeutics for the treatment of renin-angiotensin system and phosphoinositide 3-kinase malignancies in the United States. The company develops BBO-8520, an orally bioavailable small molecule direct inhibitor, which is in Phase I clinical trial for the treatment of patients with KRASG12C...
Can you invest in BridgeBio Oncology Therapeutics Inc.?
Yes. BridgeBio Oncology Therapeutics Inc. is publicly traded on NASDAQ under the ticker BBOT.
View deeper analysis
View detailed research on MarketSnap, including financials, valuation tools, and analyst context.
Open research for BridgeBio Oncology Therapeutics Inc.
Detailed equity research is provided by MarketSnap.